Nimotop (Nimodipine)

Nimodipine selectively blocks L‑type calcium channels in the smooth muscle of cerebral arteries. This reduces calcium entry, causing vasodilation of intracranial vessels, which improves perfusion and lowers the chance of vasospasm after a subarachnoid bleed.

The dosing regimen for Nimotop is determined by the treating physician based on the patient’s clinical condition, weight, and response. No fixed public dose is provided; prescribers set the appropriate infusion rate and duration.

Safety data for nimodipine in pregnancy and lactation are limited. It should only be used if the potential benefit justifies any possible risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To request Nimotop, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and import documentation.

Nimodipine is more selective for cerebral vessels than many other calcium channel blockers, resulting in fewer peripheral hypotensive effects. This selectivity makes it the preferred agent for preventing vasospasm after subarachnoid hemorrhage, whereas other blockers are generally used for systemic hypertension.

Nimotop should be stored at ambient temperature, below 25 °C, in its original packaging. Protect the product from moisture, direct sunlight, and extreme temperature fluctuations to maintain stability.

Nimotop is given as an intravenous infusion under medical supervision. The infusion rate and duration are set by the prescribing clinician, and patients are monitored continuously for blood pressure and cardiac status during administration.

The most serious adverse events include severe hypotension, myocardial infarction or ischemia, hepatic dysfunction, and rare but potentially life‑threatening allergic reactions such as anaphylaxis. Prompt recognition and management are essential.

Nimotop is contraindicated in patients with known hypersensitivity to nimodipine or any component of the formulation, those with uncontrolled severe hypotension, recent myocardial infarction, or unstable cardiac disease. Caution is also advised in severe hepatic impairment.